Outcomes in clinically relevant patient subgroups from the EMBRACA study: Talazoparib vs physician's choice standard-of-care chemotherapy

Hope S. Rugo*, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalves, Kyung Hun Lee, Louis Fehrenbacher, Lida A. Mina, Sami Diab, Natasha E. Woodward, Rinat Yerushalmi, Annabel Goodwin, Joanne L. Blum, Miguel Martin, Ruben G.W. Quek, Iulia Cristina Tudor, Helen Bhattacharyya, Eric Gauthier, Jennifer K. Litton, Wolfgang Eiermann

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'Outcomes in clinically relevant patient subgroups from the EMBRACA study: Talazoparib vs physician's choice standard-of-care chemotherapy'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry